FUJIFILM to inject $200m in cell therapy manufacturing expansion in US

TAGS

FUJIFILM Corporation has announced a substantial investment of USD 200 million to significantly enhance global cell therapy contract development and manufacturing (CDMO) capabilities. This strategic move aims to bolster the company’s position in the rapidly growing cell therapy market, projected to surge by over 30% annually from its current valuation of USD 3.3 billion.

The investment targets the new headquarters of FUJIFILM Cellular Dynamics, Inc., a pioneer in human induced pluripotent stem cell (iPSC) technology, and the California facility of FUJIFILM Diosynth Biotechnologies, a leader in biologic and advanced therapy CDMO services.

See also  Nature's Bounty launches new 30g ready-to-drink Pure Protein shakes

Key Details of the Investment

  • FUJIFILM Cellular Dynamics, Inc. in Madison, Wisconsin, will receive a new 175,000 sq. ft headquarters, doubling the company’s manufacturing capacity for iPSC-derived cell therapies.
  • FUJIFILM Diosynth Biotechnologies in Thousand Oaks, California, will expand with new development labs and additional manufacturing clean rooms, increasing its capacity for diverse cell therapies.
FUJIFILM to invest $200m in cell therapy manufacturing expansion in US

FUJIFILM to invest $200m in cell therapy manufacturing expansion in US

Impact on Cell Therapy Industry

Cell therapies, known for their potential to augment, repair, or replace human biology, are a focus of over 500 clinical trials worldwide. FUJIFILM’s investment is set to enhance its manufacturing capabilities for a range of cell therapies, including iPSC-derived therapies, Cytoxic T lymphocytes (CTL), Chimeric antigen receptor (CAR) T cells, T-cell receptor (TCR) therapies, Natural killer (NK) cells, and tissue-derived therapies.

See also  2nd STREET USA to shortly open new outlet in Frisco, Texas

Statements from FUJIFILM Corporation

Teiichi Goto, president and CEO of FUJIFILM Corporation, emphasized the investment’s role in positioning Fujifilm as a leading manufacturing partner in the cell therapy market. “We look forward to supporting our customers in manufacturing cell therapies that address unmet medical needs and contribute to the advancement of human health worldwide,” Goto stated.

See also  Ohio's children in danger: The frightening reality of White Lung Syndrome

Investment Summary and Timeline

  • FUJIFILM Cellular Dynamics’ new site will be operational in spring 2026.
  • FUJIFILM Diosynth Biotechnologies’ expanded capacity will be ready in early 2025.
CATEGORIES
TAGS
Share This

COMMENTS

Wordpress (0)